Themis Medicare Limited THEMISMED NSEPHARMA

Healthcare · Drug Manufacturers - Specialty & Generic · India

https://www.themismedicare.com

Themis Medicare Limited, together with its subsidiaries, manufactures and sells pharmaceutical products in India and internationally. It offers active pharmaceutical ingredients (APIs) and formulations used in various therapeutic areas, including anti-tuberculosis, analgesic and anti-inflammatory, analgesic and antispasmodic, analgesics, anesthesia, antacid-antiflatulent, anti-fungal, antibiotic, anti-diabetic, anti-emetic, anti-hypertensive, anti-allergic and anti-inflammatory, anti-allergic and appetite stimulant, anticoagulant, antifibrolytic, antimalarial, anti-muscarinic, antioxidant, calcium, cardiovascular, corticosteroid, electrolytes, expectorant, hematinic, hemostatic agent, hemostatic agent with anesthetic, hormones, immunomodulator with anti-viral, muscle relaxant, narcotic analgesic, neuropathy, nutraceuticals, PPI, probiotic, reversal for muscle relaxant, sedatives, skeletal muscle relaxant, skeletal muscle relaxant and analgesic and anti-inflammatory, vasodilator, vasopressors, and vitamins. The company was formerly known as Themis Chemicals and changed its name to Themis Medicare Limited in 2001. Themis Medicare Limited was founded in 1952 and is based in Mumbai, India.

Market & Price

Market Cap

₹1,017.63 Cr

Current Price

₹109.56

High / Low (52W)

₹145.95 / ₹66.07

Beta

0.42

Valuation

Stock P/E

Industry PE

37.60

Forward P/E

PEG Ratio

Book Value

₹40.99

Price to Book

2.67

P/S

3.02

EV/EBITDA

-100.56

Dividend Yield

0.44%

Profitability & Returns

ROCE

11.15%

ROE

ROA

Profit Margin

-5.16%

Op Margin

7.99%

EPS (Latest Qtr)

₹1.09

EPS (TTM)

₹-1.90

Balance Sheet & Liquidity

Debt/Equity

0.25

Quick Ratio

Current Ratio

Debt

₹95.56 Cr

Total Assets

₹588.03 Cr

Current Assets

₹303.87 Cr

Working Capital

₹147.74 Cr

Ownership

Promoter Holding

75.96%

Chg in Prom Hold

FII / Inst Holding

0.05%

Chg in FII Hold

Financial Snapshot

Enterprise Value

₹1,127.96 Cr

Total Revenue (TTM)

₹337.41 Cr

EBITDA

₹-11.22 Cr

Free Cash Flow

Operating Cash Flow

Shares Outstanding

₹9.21 Cr

Gross Margin

61.88%

Payout Ratio

15.43%

Growth (CAGR)

Revenue 5Y

0.74%

Profit 5Y

-25.75%

Revenue (YoY)

-3.90%

Earnings (YoY)

1,716.70%

PROS

No notable strengths flagged.

CONS

Earnings shrank at -25.8% CAGR over 5 years.
In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

Price Chart

NSE TradingView Screener.in

Fundamental Growth

Period: Metric:

Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP ₹	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	THEMISMED Themis Medicare Limited NSEPHARMA	109.56	-	₹1,017.63 Cr	0.44%	11.15%	-	0.74%	-25.75%
2	SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA	1,799.20	37.59	₹4.32 L Cr	0.92%	17.94%	14.72%	10.39%	10.65%
3	DIVISLAB Divi's Laboratories Limited NSEPHARMA	6,667.00	68.97	₹1.77 L Cr	0.45%	18.96%	16.19%	11.27%	12.08%
4	TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA	4,410.80	68.96	₹1.49 L Cr	0.86%	9.06%	16.98%	13.27%	20.21%
5	CIPLA Cipla Limited NIFTY50NSEAIPHARMA	1,401.00	29.16	₹1.13 L Cr	0.93%	14.88%	11.74%	7.23%	11.45%
6	DRREDDY Dr. Reddy's Laboratories Limited NIFTY50NSEAIPHARMA	1,303.50	25.90	₹1.09 L Cr	0.61%	14.00%	11.83%	10.96%	-2.35%
7	ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA	1,077.70	21.51	₹1.08 L Cr	0.09%	19.24%	18.32%	16.55%	36.99%
8	LUPIN Lupin Limited NIFTY_MIDNSEPHARMA	2,267.70	19.49	₹1.04 L Cr	0.53%	28.42%	26.91%	19.10%	131.46%
9	MANKIND Mankind Pharma Limited NIFTY_MIDNSEPHARMA	2,375.60	51.29	₹98,090.71 Cr	0.08%	13.78%	12.45%	17.73%	14.28%

Quarterly Results

Figures in INR.

Metric	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025
Revenue	-	93.81 Cr	66.27 Cr	97.58 Cr	77.99 Cr	90.13 Cr
Cost of Revenue	-	28.50 Cr	22.74 Cr	52.40 Cr	24.15 Cr	29.18 Cr
Gross Profit	-	65.31 Cr	43.53 Cr	45.18 Cr	53.85 Cr	60.96 Cr
Operating Expenses	-	59.32 Cr	51.81 Cr	57.81 Cr	59.51 Cr	53.75 Cr
Operating Income	-	5.99 Cr	-8.28 Cr	-12.63 Cr	-5.66 Cr	7.21 Cr
EBITDA	-	6.99 Cr	-7.69 Cr	-9.04 Cr	1.89 Cr	15.73 Cr
Interest Expense	-	2.79 Cr	90.31 L	2.47 Cr	2.76 Cr	2.75 Cr
Pretax Income	-	1.66 Cr	-11.13 Cr	-14.06 Cr	-3.45 Cr	10.39 Cr
Tax Provision	-	1.14 Cr	-1.46 Cr	15.52 L	16.49 L	29.42 L
Net Income	-	51.93 L	-9.66 Cr	-14.22 Cr	-3.62 Cr	10.09 Cr
Diluted EPS	1.55	0.06	-	-1.54	-0.39	1.09

Profit & Loss (Annual)

Figures in INR.

Metric	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Revenue	391.35 Cr	344.45 Cr	376.63 Cr	400.08 Cr
Cost of Revenue	151.99 Cr	121.00 Cr	139.76 Cr	134.14 Cr
Gross Profit	239.35 Cr	223.46 Cr	236.87 Cr	265.94 Cr
Operating Expenses	153.20 Cr	166.50 Cr	197.61 Cr	226.78 Cr
Operating Income	86.16 Cr	56.96 Cr	39.26 Cr	39.15 Cr
EBITDA	111.28 Cr	91.00 Cr	73.32 Cr	58.10 Cr
Interest Expense	6.54 Cr	7.99 Cr	7.63 Cr	8.49 Cr
Pretax Income	95.26 Cr	72.51 Cr	53.44 Cr	39.67 Cr
Tax Provision	22.38 Cr	15.61 Cr	9.92 Cr	9.84 Cr
Net Income	72.88 Cr	56.90 Cr	43.52 Cr	29.83 Cr
Diluted EPS	7.91	6.17	4.72	3.24

Compounded Sales Growth

5 Years:	0.74%
1 Year:	-3.90%

Compounded Profit Growth

5 Years:	-25.75%
1 Year:	1,716.70%

Stock Price Performance

1 Year:	-20.80%
6 Months:	+4.02%
3 Months:	+22.73%
1 Month:	+16.84%

Balance Sheet (Annual)

Figures in INR.

Metric	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Total Assets	427.78 Cr	513.96 Cr	566.42 Cr	588.03 Cr
Current Assets	214.16 Cr	264.53 Cr	293.17 Cr	303.87 Cr
Cash & Equivalents	20.28 Cr	12.55 Cr	9.92 Cr	6.56 Cr
Inventory	60.81 Cr	68.95 Cr	70.57 Cr	84.31 Cr
Receivables	100.56 Cr	145.02 Cr	177.95 Cr	177.10 Cr
Total Liabilities	140.29 Cr	174.51 Cr	188.75 Cr	185.43 Cr
Current Liabilities	109.52 Cr	139.13 Cr	152.98 Cr	156.12 Cr
Long Term Debt	22.31 Cr	26.70 Cr	25.13 Cr	16.88 Cr
Total Debt	79.73 Cr	92.38 Cr	95.79 Cr	82.99 Cr
Total Equity	287.49 Cr	339.44 Cr	377.67 Cr	402.60 Cr
Shares Outstanding	9.20 Cr	9.20 Cr	9.20 Cr	9.20 Cr

Cash Flows (Annual)

Figures in INR.

Metric	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Operating Cash Flow	34.39 Cr	16.09 Cr	22.09 Cr	34.71 Cr
Investing Cash Flow	-15.59 Cr	-23.96 Cr	-15.95 Cr	-12.17 Cr
Financing Cash Flow	-17.55 Cr	13.62 L	-8.77 Cr	-25.90 Cr
Capital Expenditure	-20.63 Cr	-28.75 Cr	-18.42 Cr	-15.43 Cr
Free Cash Flow	13.77 Cr	-12.66 Cr	3.68 Cr	19.28 Cr
Net Change in Cash	1.26 Cr	-7.73 Cr	-2.62 Cr	-3.36 Cr

Ratios (Annual)

Figures in %.

Metric	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Gross Margin %	61.2%	64.9%	62.9%	66.5%
Operating Margin %	22.0%	16.5%	10.4%	9.8%
Net Margin %	18.6%	16.5%	11.6%	7.5%
ROE %	25.4%	16.8%	11.5%	7.4%
ROCE %	27.1%	15.2%	9.5%	9.1%

Shareholding Pattern

Insiders

75.96%

Institutions

0.05%

Public Float

0.20%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for THEMISMED

No recent headlines available.

THEMISMED · Healthcare